Cardio/Kidney Composite End Points: A Post Hoc Analysis of the EMPA‐REG OUTCOME Trial
Open Access
- 6 April 2021
- journal article
- research article
- Published by Wolters Kluwer Health in Journal of the American Heart Association
- Vol. 10 (7) , e020053
Abstract
Background: Cardio/kidney composite end points are clinically relevant but rarely analyzed in cardiovascular trials. This post hoc analysis of the EMPA‐REG OUTCOME (Empagliflozin Cardiovascular Outcome Event Trial in Type 2 Diabetes Mellitus Patients) trial evaluated cardio/kidney composite end points by 2 statistical approaches. Methods and Results: A total of 7020 patients with type 2 diabetes mellitus and established cardiovascular disease were treated with empagliflozin 10 or 25 mg (n=4687) or placebo (n=2333) on top of standard care. Cardio/kidney composite end points studied were: (1) cardiac or kidney death, kidney failure, hospitalization for heart failure, sustained decline in estimated glomerular filtration rate ≥40% from baseline, or sustained progression to macroalbuminuria; (2) cardiac or kidney death, kidney failure, hospitalization for heart failure, or sustained estimated glomerular filtration rate decline ≥40% from baseline; and (3) cardiac or kidney death, kidney failure, hospitalization for heart failure, or sustained doubling in serum creatinine from baseline. Cox regression using time‐to‐first‐event analysis and win ratio (WR) using hierarchical order of events were applied. Empagliflozin reduced the risk of all cardio/kidney composites. The results varied only slightly between Cox and WR (eg, composite 1: hazard ratio, 0.56 [95% CI, 0.49–0.64]; WR, 1.76 [95% CI, 1.53–2.02]. WR prioritizes events by clinical importance; in particular, all fatal events are evaluated, whereas Cox regression ignores deaths when preceded by nonfatal events. Of the 285 cardio/kidney deaths in the analysis, 44 to 56 (15%–20%), depending on the composite, occurred after a nonfatal event and were not evaluated in Cox regression but evaluated by the WR. Conclusions: By considering the clinical relevance of different event types, the WR represents an appropriate method to complement the traditional time‐to‐first‐event analysis in cardio/kidney outcomes. Registration: URL: https://www.clinicaltrials.gov ; Unique identifier: NCT01131676.Keywords
This publication has 10 references indexed in Scilit:
- Challenges of Cardio-Kidney Composite Outcomes in Large-Scale Clinical TrialsCirculation, 2021
- The win ratio approach for composite endpoints: practical guidance based on previous experienceEuropean Heart Journal, 2020
- Use of the Win Ratio in Cardiovascular TrialsJACC: Heart Failure, 2020
- Cardiorenal Syndrome RevisitedCirculation, 2018
- Empagliflozin and Progression of Kidney Disease in Type 2 DiabetesNew England Journal of Medicine, 2016
- Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 DiabetesNew England Journal of Medicine, 2015
- The win ratio: a new approach to the analysis of composite endpoints in clinical trials based on clinical prioritiesEuropean Heart Journal, 2011
- Problems with use of composite end points in cardiovascular trials: systematic review of randomised controlled trialsBMJ, 2007
- Combining mortality and longitudinal measures in clinical trialsStatistics in Medicine, 1999
- Regression Models and Life-TablesJournal of the Royal Statistical Society Series B: Statistical Methodology, 1972